| 178 |
Haloperidol
|
-
Haloperidol, CAS-RN: 52-86-8, DTXSID4034150
|
170: Anti-dopaminergic activity leading to mammary adenomas and carcinomas in the SD rat
|
| 351 |
Halothane
|
-
Halothane, CAS-RN: 151-67-7, DTXSID4025371
|
260: CYP2E1 activation and formation of protein adducts leading to neurodegeneration
|
| 620 |
HCoV-NL63
|
|
2 AOPs
|
| 675 |
Heavy metals (cadmium, lead, copper, iron, nickel)
|
|
3 AOPs
|
| 276 |
Helicobacter pylori
|
|
217: Gastric ulcer formation
|
| 299 |
Helicobacter pylori infection
|
|
229: Helicobacter pylori to gastric ulcer
|
| 344 |
Heptachlor
|
-
Heptachlor, CAS-RN: 76-44-8, DTXSID3020679
|
10: Binding to the picrotoxin site of ionotropic GABA receptors leading to epileptic seizures in adult brain
|
| 150 |
Hexachlorobenzene
|
-
Hexachlorobenzene, CAS-RN: 118-74-1, DTXSID2020682
|
131: Aryl hydrocarbon receptor activation leading to uroporphyria
|
| 500 |
High aspect ratio material
|
|
2 AOPs
|
| 646 |
high fat diet
|
|
403: combined unhealthy lifestyle factors leading to metabolic syndrome
|
| 503 |
High LET Ra
|
|
None
|
| 504 |
High LET Radiation
|
|
None
|
| 610 |
HMR3480
|
|
None
|
| 623 |
Hy
|
|
None
|
| 446 |
Hydralazine hydrochloride
|
-
Hydralazine hydrochloride, CAS-RN: 304-20-1, DTXSID1044645
|
2 AOPs
|
| 132 |
Hydrocarbons, various
|
|
None
|
| 454 |
Hydrogen peroxide
|
-
Hydrogen peroxide, CAS-RN: 7722-84-1, DTXSID2020715
|
296: Oxidative DNA damage leading to chromosomal aberrations and mutations
|
| 514 |
Hydroquinone
|
-
Hydroquinone, CAS-RN: 123-31-9, DTXSID7020716
|
296: Oxidative DNA damage leading to chromosomal aberrations and mutations
|
| 82 |
Ibuprofen
|
-
Ibuprofen, CAS-RN: 15687-27-1, DTXSID5020732
|
177: Cyclooxygenase 1 (COX1) inhibition leading to renal failure and mortality
|
| 777 |
Ifosfamide
|
-
Ifosfamide, CAS-RN: 3778-73-2, DTXSID7020760
|
532: CYP450 upregulation leads to Chronic kidney disease
|
| 614 |
iguratimod
|
-
Iguratimod, CAS-RN: 123663-49-0, DTXSID0048971
|
277: Impaired IL-1R1 signaling leading to Impaired T-Cell Dependent Antibody Response
|
| 489 |
IL-1 receptor antagonist(IL-1Ra)(Anakinra)
|
|
277: Impaired IL-1R1 signaling leading to Impaired T-Cell Dependent Antibody Response
|
| 438 |
IL-1 receptor antagonist(IL-1Ra)(Anakinra), anti-IL-1b antibody (Canakinumab), soluble IL-1R (Rilonacept)
|
|
None
|
| 519 |
Imiquimod
|
-
Imiquimod, CAS-RN: 99011-02-6, DTXSID7041047
|
313: Stimulation of TLR7/8 in dendric cells leading to Psoriatic skin disease
|
| 119 |
Immepip
|
|
None
|